Terri Lynn Parker MD

Assistant Professor of Medicine (Hematology); Assistant Professor

Specialties & Subspecialties

Cancer Center, Yale: Hematology Program

Hematology

Education & Training

  • B.S., University of Pittsburgh (2001)
  • M.D., St. George's University School of Medicine Grenada (2005)
  • Residency, University of Connecticut Health Center , Internal Medicine  (2005 - 2008)
  • Fellowship, University of Connecticut Health Center , Hospice and Palliative Med  (2008 - 2009)
  • Fellowship, Yale University School of Medicine , Hematology and Medical Oncology  (2009 - 2012)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | NA


Clinical Interests

Benign and Malignant Hematology; Hospice and Palliative Medicine


Cancers Treated

Leukemia


Board Certifications

  • Hospice & Palliative Medicine, Board Certified (2010)
  • Hematology, Internal Medicine, Board Certified (2012)
  • Internal Medicine, Board Certified (2008)

Clinical Trials

Conditions Study Title
Ill-Defined Sites and Unknown Sites A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
Leukemia, not otherwise specified and Myeloid and Monocytic Leukemia An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Leukemia, other Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML
Non-Hodgkin's Lymphoma Phase 1 Dose Finding Study of Belinostat plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients with Peripheral T cell Lymphoma (PTCL)

Edit Profile